Results 11 to 20 of about 4,919,522 (294)

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials [PDF]

open access: yes, 2009
Background Low-dose aspirin is of definite and substantial net benefit for many people who already have occlusive vascular disease. We have assessed the benefits and risks in primary prevention.
Bubes, V   +34 more
core   +4 more sources

Secondary stroke prevention: challenges and solutions

open access: yesVascular Health and Risk Management, 2015
Charles Esenwa, Jose GutierrezDepartment of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USAAbstract: Stroke is the leading cause of disability in the USA and a major cause of mortality worldwide.
Esenwa C, Gutierrez J
doaj   +1 more source

Antiplatelet Therapy for Secondary Stroke Prevention in Patients with Ischemic Stroke or Transient Ischemic Attack [PDF]

open access: yes, 2021
The risk of stroke recurrence is highest in the acute phase after transient ischemic attack (TIA) or ischemic stroke. Therefore, patients with TIA or ischemic stroke should be treated with antiplatelet medication for stroke prevention. The short-term use
이경열
core   +1 more source

The use of behaviour change theory for infection prevention and control practices in healthcare settings: a scoping review [PDF]

open access: yes, 2022
Background Infection prevention and control (IPC) practices performed by healthcare workers are key to the prevention and management of infections.
Greene, Carolynn, Wilson, Jennie
core   +1 more source

Utility and limitations of ejection fraction and of diastolic dysfunction in heart failure patients

open access: yesMonaldi Archives for Chest Disease, 2019
The echocardiographic evaluation of left ventricular (LV) systolic function, and especially of ejection fraction (EF) plays a central role in the diagnosis of heart failure (HF) due to its undisputed prognostic value. Limitations of EF are substantially:
Gian Francesco Mureddu, Andrea Faggiano
doaj   +1 more source

RESULTS OF THE CLINICAL TRIAL FOURIER. NEW OPPORTUNITIES FOR TREATMENT OF VERY HIGH CARDIOVASCULAR RISK PATIENTS

open access: yesРоссийский кардиологический журнал, 2017
Advisory Board of Russian Society of Cardiology (RSC), Russian National Atherosclerosis Society (RNAS), Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention (RSCRSP)
Advisory Board
doaj   +1 more source

Primary and secondary prevention of breast cancer [PDF]

open access: yes, 2017
Introduction Breast cancer is the most common cancer among women and is the second cancer frequently occurring worldwide of newly-diagnosed cancers. There is much evidence showing the influence of life style and environmental factors on the development ...
Franciszek Burdan   +13 more
core   +2 more sources

A UK consensus on optimising CVD secondary prevention care: perspectives from multidisciplinary team members [PDF]

open access: yes, 2019
Although overall cardiovascular (CV) mortality has declined in recent years, patients with clinically manifest cardiovascular disease (CVD) remain at increased risk of recurrent CV events. To minimise the likelihood of future CV events following an acute
The ICON (Integrating Care Opportunities across the NHS) CVD Secondary Prevention Working Group
core   +1 more source

Cluster randomized trial in the general practice research database: 2. Secondary prevention after first stroke (eCRT study): study protocol for a randomized controlled trial. [PDF]

open access: yes, 2012
BACKGROUND: The purpose of this research is to develop and evaluate methods for conducting pragmatic cluster randomized trials in a primary care electronic database.
Wolfe Charles   +34 more
core   +2 more sources

Comparing primary prevention with secondary prevention to explain decreasing Coronary Heart Disease death rates in Ireland, 1985-2000. [PDF]

open access: yes, 2007
BACKGROUND: To investigate whether primary prevention might be more favourable than secondary prevention (risk factor reduction in patients with coronary heart disease(CHD)).
Kabir Z   +30 more
core   +2 more sources

Home - About - Disclaimer - Privacy